Open Payments and Aesthetic Medicine: What Drug and Device Makers Pay Your Doctor

When a dermatologist recommends a specific brand of wrinkle relaxer, or a plastic surgeon suggests a particular dermal filler family, patients expect that recommendation to be based purely on clinical efficacy and suitability. Yet behind the scenes of the medical aesthetics industry, a complex web of financial relationships exists between the manufacturers of these products and the physicians who inject them. From funding clinical trials and paying royalties on patented techniques to hosting advisory boards at luxury resorts and ordering catered lunches for clinic staff, millions of dollars change hands annually.

For years, these transactions remained invisible to the public. Today, the federal Physician Payments Sunshine Act and state-level mandates like California's Assembly Bill 1278 (AB 1278) have made these financial ties fully transparent.

This guide details how the federal Open Payments database tracks financial relationships in aesthetic medicine. We analyze which aesthetic drug and device companies pay the most, explain how patients can look up their own injectors, break down the strict patient-disclosure rules now facing California clinics, and address the critical question of whether industry payments influence clinical care.

---

What is the Open Payments (Sunshine Act) database and what does it require aesthetic manufacturers to report?

The Open Payments program is a national transparency registry administered by the Centers for Medicare & Medicaid Services (CMS). Established under Section 1128G of the Social Security Act—originally enacted as part of the 2010 Patient Protection and Affordable Care Act (commonly known as the Sunshine Act)—the program is designed to expose financial relationships between the pharmaceutical and medical device industries and healthcare providers.

The law requires all applicable drug, device, biological, and medical supply manufacturers that participate in federal healthcare programs to report annually essentially all "transfers of value" made to covered recipients.

Who Must Report and Who is Covered?

The reporting obligation falls entirely on the manufacturers. If an aesthetic company sells a product in the United States, they must log every payment or transfer of value they make.

• Covered Recipients: Historically, the law only covered licensed physicians (MDs and DOs) and teaching hospitals. However, starting with the 2021 program year (data published in 2022), the definition of "covered recipient" expanded to include mid-level practitioners: Physician Assistants (PAs), Nurse Practitioners (NPs), Clinical Nurse Specialists, Certified Registered Nurse Anesthetists, and Certified Nurse-Midwives. This expansion is highly significant for the medical aesthetics sector, where PAs and NPs perform a substantial percentage of injectable and laser procedures.
• The Reporting Threshold: The statutory reporting threshold is extremely low. The Affordable Care Act set a base of $10 for any single transfer of value and roughly $100 in aggregate per practitioner per year, and CMS inflation-adjusts those amounts annually. For the 2024 program year, the figures were $13.07 per single payment and $130.66 for the annual aggregate. If the cumulative annual value of small items (each under the single-payment threshold) provided to one practitioner exceeds the aggregate limit, the manufacturer must report all of them.

What Must Be Reported?

Manufacturers must log the recipient’s name, primary business address, National Provider Identifier (NPI), state license number, specialty, the exact payment amount, the date, and the "Nature of Payment." The CMS registry categorizes the nature of payments into specific buckets:

• General Payments: Non-research payments, including consulting fees, speaker fees (honoraria), food and beverage (lunches provided to clinics), travel and lodging, education, gifts, entertainment, and royalties or licensing fees.
• Research Payments: Funding for clinical studies, clinical trial coordination, and research grants.
• Ownership or Investment Interests: Stock, stock options, or partnership shares held by a physician or their immediate family members in the manufacturing company.

CMS updates the public database annually, typically on or near June 30, publishing the complete data set from the preceding calendar year.

---

How much do aesthetic manufacturers actually pay dermatologists and plastic surgeons, and which company pays the most?

Financial transactions in medical aesthetics are highly concentrated, reflecting the commercial power of a few key pharmaceutical and device conglomerates. Nationally, dermatology and plastic surgery are among the highest-paid specialties by industry. Peer-reviewed research indicates that industry payments to dermatologists alone totaled approximately $278 million over the five-year period from 2017 to 2021 (Cutis/MDEdge, 2024). Across all specialties, more than half of licensed US physicians received at least one industry payment (JAMA, 2024).

California 2024 Data: A Striking Case Study in Aesthetic Concentration

To understand how this money is distributed in a single, high-volume aesthetic market, we performed a targeted analysis of the CMS 2024 general payments dataset, isolating payments made by the principal aesthetic manufacturers to licensed dermatologists and plastic surgeons in the state of California.

In 2024, aesthetic manufacturers made 25,600 general payments to California dermatologists and plastic surgeons, totaling $13,625,734.48.

When we group these payments by submitting manufacturer, a dramatic pattern of market dominance emerges:

Note: Allergan Aesthetics is normalized to include AbbVie submitting entities. Data represents 2024 general payments to California dermatologists and plastic surgeons.

Allergan’s $11.5 Million California Footprint

Allergan / AbbVie—the maker of Botox Cosmetic, the Juvéderm filler collection, CoolSculpting, and Skinvive—accounts for 85.9% of all aesthetic manufacturer spend in the California specialist registry. This $11.7 million footprint is built on two parallel strategies: a massive volume of low-value touchpoints (over 19,700 individual transactions, primarily clinic staff meals and local dinner meetings) and a small number of extremely high-value intellectual property arrangements.

When we break down the Nature of Payment across all aesthetic manufacturers in the California specialist dataset, we see where the money actually goes:

Royalty or License:                 $7,420,904.46
Compensation for Services (Faculty):$2,595,107.85
Consulting Fee:                     $2,263,899.46
Food and Beverage:                  $768,419.18
Travel and Lodging:                 $365,566.11
Grant:                              $119,150.00

The data shows that the absolute majority of aesthetic spend in California ($7.42 million) is paid under Royalty or License. This reflects patents and licensing agreements held by key academic and clinical leaders who helped develop modern injection techniques or device applications.

The next largest categories are Compensation for Services ($2.60 million) and Consulting Fee ($2.26 million). These represent fees paid to physician trainers, advisory board members, and investigators who lead clinical trials.

By contrast, Food and Beverage accounts for a relatively small dollar total ($768,419.18), but represents the vast majority of the individual transaction counts. These are the catered lunches and dinners provided by sales representatives to clinics, used to gain access to staff and keep their brands front-of-mind.

---

How does a patient look up their injector or surgeon in Open Payments?

For patients, the CMS Open Payments database is a powerful due-diligence tool that can be accessed for free. By inspecting the registry, a patient can determine if their doctor has a financial relationship with the company that makes the products they recommend.

Step-by-Step Search Protocol

1. Navigate to the official CMS Open Payments search portal: openpaymentsdata.cms.gov/search.
2. Select the Physician Search tab.
3. Enter the physician's first and last name. You can filter by state (e.g., "CA") or enter their city to narrow the results if the name is common.
4. Click Search.
5. Select the correct profile from the results list.

Interpreting the Results Profile

A physician's profile page displays three primary tabs corresponding to the CMS reporting categories: General Payments, Research Payments, and Associated Research.

• The Summary Box: At the top of the page, CMS displays the total dollar amount received by the physician for the selected program year, the number of individual payments, and how their payments rank compared to peers in their specialty.
• The Manufacturer Breakdown: The profile shows a pie chart and list detailing which companies paid the physician. For aesthetic patients, look for names like Allergan, Galderma, Evolus, Revance, or device manufacturers like Solta, Candela, Cynosure, or InMode.
• Evaluating the nature of payments: If a doctor has received $50,000 from Allergan, check the category.
  • If the $50,000 is under Research, it means the doctor’s clinic is an active clinical trial site helping test new products under FDA supervision.
  • If it is under Consulting Fees or Compensation for Services, the doctor is likely a "Key Opinion Leader" (KOL) who speaks at conferences, trains other injectors, or advises the company.
  • If it is dominated by small entries under Food and Beverage, the doctor is not a key advisor, but their clinic routinely accepts lunches from company sales reps.

---

What is California AB 1278 and what does it require aesthetic practices to do?

While federal law requires manufacturers to report payments, it does not force doctors to tell their patients about the database. California changed this dynamic.

Signed into law in 2022, California Assembly Bill 1278 (AB 1278)—codified under California Business and Professions Code Section 2420—mandates that all licensed physicians and surgeons in California provide explicit, proactive notice to patients regarding the federal Open Payments database.

AB 1278 took effect on 1 January 2024, and compliance is mandatory for all California dermatologists, plastic surgeons, and medical directors supervising med spas.

The Three Disclosure Mandates

California physicians must meet three separate notice requirements:

1. In-Person Written Notice: At a patient's initial visit, the practice must present a written disclosure statement. The patient (or their representative) must sign and date the notice. The signed disclosure must be kept in the patient’s medical record. The law prescribes the exact wording of the notice:

   "The Open Payments database is a federal tool used to search payments made by drug and device enterprises to physicians and teaching hospitals. It can be found at https://openpaymentsdata.cms.gov."

2. Physical Office Signage: The practice must post a clear, visible sign at each office location where the physician meets with patients. The sign must be at least 8.5 by 11 inches, printed in at least 22-point font, and placed in a conspicuous area (such as the reception desk or waiting room). It must contain the mandatory Open Payments notice text.
3. Website Disclosure: If the physician or the medical practice maintains a public website, the home page (or a clearly marked, easily accessible sub-page) must display the mandatory Open Payments notice, including a direct link to the CMS search tool.

Compliance Risks and Enforcement

In reality, the California Medical Board and the Osteopathic Medical Board of California treat violations of AB 1278 as unprofessional conduct. Under California law, a single documented failure to provide the AB 1278 notice can lead to disciplinary action against the physician's license, administrative fines, and public record listings of non-compliance.

Furthermore, because California med spas operate under the supervision of a licensed physician (acting as a Medical Director), the Medical Director's license is directly at risk if the clinic they supervise fails to collect signed patient disclosures or display the mandatory waiting-room signs.

---

What is NOT reported in the Open Payments database?

While the Sunshine Act captures a vast array of financial transactions, the law designates specific exceptions and transfers of value that manufacturers do not have to report. Understanding these exclusions helps patients and providers put the database into context:

1. Short-Term Product Samples: Manufacturers do not have to report the value of pharmaceutical or biological samples provided to a physician for patient use. For example, if a dermatologist receives sample tubes of a new topical retinoid cream or samples of a prescription skin barrier ointment to distribute to patients for post-procedure recovery, these are excluded from reporting. However, this exception does not apply to full-size aesthetic injectables (like Botox vials or Juvéderm syringes) used for in-office treatments.
2. Patient Demonstration Units: Device manufacturers can provide educational models or demonstration units (such as a non-functional laser handpiece or a silicone breast implant sample shell) to clinics for patient education without reporting their value, as long as the items cannot be used on patients.
3. In-Kind Educational Materials: Educational materials directly intended for patient use or benefit (such as anatomical brochures, before-and-after photo booklets, or patient instruction cards) are excluded from the reporting obligation.
4. General Discount and Rebate Programs: Volume-based price discounts and rebate structures on bulk product orders (such as purchase discounts on laser systems or bulk filler orders) are commercial transactions between the practice and the manufacturer, not personal transfers of value to the physician, and are therefore not reported in the individual physician’s Open Payments registry.
5. Accidental Payments Under the De Minimis Limit: Single payments below the per-payment threshold (inflation-adjusted to $13.07 for the 2024 program year) do not need to be reported unless the cumulative value of all minor payments from that manufacturer to the provider exceeds the annual aggregate limit ($130.66 for 2024).

These exclusions mean that while the Open Payments database provides a highly comprehensive picture of personal compensation, speaker honoraria, travel, and meals, it does not document the general commercial trade discounts or clinical sample programs that support daily practice operations.

---

Does receiving industry payments influence my doctor's recommendations?

The existence of financial relationships between aesthetic manufacturers and physicians raises a critical question for patients: Does this money introduce bias?

The Legal and Ethical Context

The HHS Office of Inspector General (OIG) has repeatedly published reports and alerts warning that financial relationships between manufacturers and prescribers can influence medical decision-making. OIG studies show that even low-value transfers of value—such as routine meals—correlate with higher rates of prescribing brand-name drugs and devices over clinical alternatives.

In medical aesthetics, the dynamics are unique:

• Cash-Pay Market: Unlike general medicine, where insurance companies control which drug is approved via formularies, aesthetics is a cash-pay market. The patient pays out-of-pocket, and the physician has absolute discretion to purchase and inject whichever product they prefer.
• The Volume Discount Structure: Manufacturers offer clinics volume-based rebate structures. If a practice purchases 500 vials of Botox per quarter, their cost per vial might drop from $600 to $510. This financial structure creates an incentive for a clinic to consolidate its portfolio under a single manufacturer (e.g., Allergan) to maximize their margin, even if a competitor’s product (e.g., Dysport or Xeomin) might be a better clinical fit for a specific patient.

How to Have the Conversation

Rather than assuming a physician is compromised because they appear in the Open Payments database, patients should use the registry to ask informed questions during their consultation:

• "I noticed on the Open Payments database that you serve as a trainer and consultant for Galderma. Does that mean you prefer Restylane over Juvéderm for this specific injection area? What are the clinical reasons for that choice?"
• "Are there alternative products from other manufacturers that would work for my treatment, and how do their safety profiles compare?"

A reputable, board-certified physician will welcome this transparency. They will explain that their consulting relationship reflects their expertise, that they were selected because they train others in safety techniques, and they will provide a clear clinical justification for why the selected product is appropriate for the patient's anatomy.

---

Summary & FAQ

Transparency in aesthetic medicine protects both patients and the integrity of the profession. Through the federal Sunshine Act and California's AB 1278, the financial relationships between manufacturers and injectors are no longer private agreements. By understanding these disclosures, patients can make more informed choices, and providers can maintain compliant, trust-based relationships with those they treat.

How do I find out if my dermatologist or plastic surgeon gets paid by Allergan or Galderma?

You can search your physician's name on the public CMS Open Payments search portal at openpaymentsdata.cms.gov. The search results will show the exact dollar amount they received, which companies paid them, and the nature of those payments (such as consulting, travel, or royalties).

What payments do aesthetic drug and device companies have to report under the Sunshine Act?

Manufacturers must report essentially any transfer of value above the inflation-adjusted de minimis threshold (about $13 per single payment and roughly $131 in aggregate per practitioner for the 2024 program year) made to licensed physicians, physician assistants (PAs), nurse practitioners (NPs), and other covered recipients. This includes consulting fees, speaker fees, travel, lodging, gifts, royalties, and meals provided to clinic staff.

Does California require my doctor to tell me about the Open Payments database?

Yes. Under California Assembly Bill 1278 (AB 1278), effective 1 January 2024, all licensed California physicians must provide a written Open Payments notice at a patient's first visit (which the patient must sign), post a physical sign in their office, and display the notice and link on their practice website.

What should a provider or med spa owner do if they identify errors in their Open Payments report?

Because manufacturers report payments unilaterally, errors in the CMS Open Payments database are relatively common. A physician or mid-level practitioner might find a payment logged for a lunch they did not attend, or a consulting fee that was reported twice. CMS provides a structured dispute resolution window each year: from April 1 to May 15, providers can review the data submitted by manufacturers and flag any inaccuracies. Once a dispute is filed through the CMS portal, the manufacturer has until May 30 to resolve it with the provider. If the manufacturer agrees it made an error, it will submit corrected data. If a dispute is not resolved before the June 30 publication date, CMS will publish the data but will mark the record as "Disputed" until the parties reach an agreement. Providers are strongly encouraged to register for the CMS portal and review their reports annually during this window.

---

Sources

1. Centers for Medicare & Medicaid Services (CMS) — Open Payments Program: Federal database of payments and transfers of value under Section 1128G of the Social Security Act. URL: openpaymentsdata.cms.gov
2. California Legislative Information — Assembly Bill No. 1278: Act adding Section 2420 to the Business and Professions Code, regarding physician disclosure of the Open Payments database. URL: leginfo.legislature.ca.gov
3. U.S. Department of Health and Human Services (HHS) — Office of Inspector General: Special advisory alerts and reports on the correlation between physician payments and prescribing patterns. URL: oig.hhs.gov
4. Peer-reviewed Analysis of Industry Payments in Dermatology: "A 5-year analysis of Open Payments data (2017 to 2021) for dermatology" (Cutis/MDEdge, 2024). URL: mdedge.com/dermatology
5. Peer-reviewed Analysis of Open Payments in Plastic Surgery: "Sunshine Act Open Payments: a 7-year analysis of trends within plastic surgery and its subspecialties" (PMC12209232). URL: ncbi.nlm.nih.gov/pmc
6. California Medical Association (CMA) — Open Payments Notice Requirements: Compliance guide for California practices under AB 1278. URL: cmadocs.org
7. McGuireWoods — Healthcare Regulatory Advisory: California's new Open Payments disclosure laws for physicians and employers. URL: mcguirewoods.com